Tracking Cathie Wood: Increasing positions in commercial spaceflight and AI healthcare, while reducing exposure to genomics and e-commerce sectors for portfolio rebalancing.

US stocks fell across the board on Tuesday (August 18). The S&P 500 closed at 7,691.76 points, down 0.69%; tech stocks suffered heavy losses, with the Nasdaq Composite falling 1.33% to 26,289.71 points; the Dow Jones Industrial Average showed relative resilience, closing at 53,343.40 points, down 0.22%. Against the backdrop of a broad market decline, investor sentiment remained cautious, and growth stocks faced significant pressure.

Facing market correction pressures, Cathie Wood's ARK chose to act contrarily, simultaneously increasing investments in multiple disruptive innovation sectors such as space exploration, AI infrastructure, precision medicine, and blockchain finance. At the same time, it rebalanced positions in certain genomics and e-commerce holdings. The overall strategy featured an "offensive stance with selective trimming."

Symbols

Buy Direction: Contrarian positioning in core targets within space, AI computing power, and precision medicine.

$Rocket Lab (RKLB.US)$ Largest single transaction of the day: purchased 160,890 shares. As a key player in the new space age, Rocket Lab's progress in developing its Neutron rocket and its growing satellite launch orders may be gradually realizing commercial value. ARK likely views the current pullback as a rare window to increase its position, maintaining a bullish outlook on the company's long-term competitiveness in the low-cost orbit sector.

$Freenome (FRNM.US)$ Purchased 59,279 shares. Freenome is deeply engaged in early-stage cancer liquid biopsy technology. If its multi-omics platform can be validated by subsequent clinical data, it has the potential to disrupt the traditional oncology screening market, aligning with ARK's core investment thesis of "exponential growth" in precision medicine.

$Tempus AI (TEM.US)$ Purchased 35,501 shares. Tempus AI deeply integrates clinical data with AI analysis, dedicated to advancing precision diagnosis and treatment for oncology and chronic diseases. Its vast medical data assets may constitute a difficult-to-replicate competitive moat. ARK likely continues to see long-term potential for valuation reshaping in its AI healthcare data platform.

$Cerebras Systems (CBRS.US)$ Purchased 35,089 shares. Cerebras is challenging the dominance of GPU computing power with its ultra-large wafer-scale architecture. Its differentiated advantages in AI training and inference are attracting attention from top AI labs. ARK's increased position may reflect its continued optimism about the non-traditional AI computing infrastructure sector.

$Securitize (SECZ.US)$ Purchased 31,340 shares. Securitize is a core infrastructure provider for the tokenization of Real World Assets (RWA). As institutional-grade blockchain applications accelerate their implementation, the value of its compliant token issuance platform may be undergoing revaluation, consistent with ARK's long-term bet on the underlying infrastructure of digital finance.

$Ionis Pharmaceuticals (IONS.US)$ Purchased 26,246 shares. Ionis has been深耕 (deeply engaged) in RNA-targeted therapies for many years. Its antisense oligonucleotide (ASO) technology platform covers multiple high-barrier indications such as neurological and cardiovascular diseases. ARK's increased stake may be based on the commercialization progress of its pipeline and the long-term scarcity of its platform technology.

$Block (XYZ.US)$ Purchased 16,810 shares. Block's Cash App and Square ecosystem continue to penetrate the decentralized finance sector. Its Bitcoin-related business layout also aligns with ARK's long-term bullish logic on crypto assets. This increase in position may be a portfolio rebalancing operation.

$Scribe Therapeutics (SCTX.US)$ Purchased 5,614 shares. Scribe focuses on the engineered development of next-generation CRISPR gene-editing technology. Its proprietary XE system may offer unique advantages in precision and delivery efficiency compared to traditional Cas9. ARK continues to monitor its differentiated technological layout in the field of gene therapy.

$Cloudflare (NET.US)$ Purchased 2,996 shares. As a global leader in cybersecurity and edge computing platforms, Cloudflare's Zero Trust security architecture plays a key role in enterprise digital transformation in the AI era. The small increase in holdings may reflect ARK's long-term conviction in its cybersecurity moat.

Sell side: Rebalancing positions in some holdings related to genomics, e-commerce, and semiconductors.

$Shopify (SHOP.US)$ Reduced holdings by 50,071 shares, marking the largest sell-off of the day. Shopify's valuation has remained elevated for an extended period. ARK's reduction likely stems from position sizing and capital reallocation needs, shifting funds toward early-stage innovative targets with more attractive valuations, rather than indicating a bearish view on its long-term prospects.

$10x Genomics (TXG.US)$ Reduced holdings by 36,478 shares. While 10x Genomics holds a technological lead in spatial genomics, it faces pressure in commercialization progress. ARK's reduction may aim to lower concentration in the single genomics sector for more balanced portfolio management.

$Illumina (ILMN.US)$ Reduced holdings by 32,648 shares. As the industry leader in gene sequencing, Illumina has faced intensified competition and regulatory uncertainty in recent years. ARK's reduction likely reflects an active adjustment to its overall exposure in the genomics sector, not a denial of Illumina's long-term technological standing.

$CareDx (CDNA.US)$ Reduced holdings by 21,947 shares. CareDx focuses on precision medicine for organ transplantation but recently faces uncertainty regarding insurance reimbursement policies. ARK's reduction may be related to lowering concentration in policy-sensitive healthcare stocks, representing a prudent risk management operation.

$AtaiBeckley (ATAI.US)$ Reduced holdings by 20,847 shares. Although ATAI Life Sciences has a forward-looking layout in innovative therapies for mental health, the pace of clinical pipeline progress and cash burn rate may have led ARK to moderately reduce its position to control investment risks in early-stage biotechnology.

$Advanced Micro Devices (AMD.US)$ Reduced holdings by 3,679 shares. AMD's competitiveness in the AI accelerator market continues to rise, but relative to earlier-stage AI computing power targets, ARK's slight reduction may reflect selective rotation within the semiconductor sector, with funds potentially tilting toward differentiated computing power directions like Cerebras.

$Brera Holdings (SLMT.US)$ Reduced holdings by 317 shares, a negligible amount, likely representing minor position adjustments within routine portfolio management.

Futubull [Opportunity Page] has launched tracking for celebrity portfolio opportunities! Choose from multiple celebrity holdings, follow big investors' layouts with one click, precisely lock in high-quality targets, and invest with greater confidence!

181K Views